Myeloperoxidase is not a good biomarker for preeclampsia prediction

L. Rocha-Penha1, H. Bettiol2, M. A. Barbieri2, V. C. Cardoso2, R. C. Cavalli3 & V. C. Sandrim1

Myeloperoxidase is a proinflammatory enzyme found to be increased in patients with established preeclampsia but never investigated before the disease onset. Here we examined myeloperoxidase concentration and activity in plasma and urine samples from pregnant women who remained normotensive throughout pregnancy and those who developed preeclampsia in order to assess its potential to predict this disorder. Our sample consisted of 30 cases who developed preeclampsia (14 severe and 16 mild) and 57 controls who remained healthy throughout pregnancy, derived from the Brazilian Ribeirão Preto and São Luís prenatal cohort (BRISA). Myeloperoxidase concentration were assessed using a commercial ELISA kit and enzymatic activity through tetramethylbenzidine oxidation. No statistical differences were found in myeloperoxidase levels nor activity between plasma or urine samples from controls, severe and mild cases. Myeloperoxidase did not seem to have a potential application for preeclampsia prediction.

Preeclampsia is a pregnancy-related disorder characterized by new-onset hypertension in association with proteinuria or other systemic signs, and is consider one of the major contributing factors for maternal and fetal morbidity1. Although some maternal characteristics are associated with increased risk for development of the disorder2, there is still no marker in clinical use for early diagnosis of this syndrome3,4.

Complexity of the disorder may be one reason for the difficulty in finding precise biomarkers. Although not fully understood, preeclampsia pathophysiology is mainly characterized in two stages starting with impaired placentation, which leads to ischemia, oxidative stress and release of bioactive factors in maternal circulation, and progressing to the second stage of maternal response when the symptoms arise5,6. Several molecules have been investigated for preeclampsia prediction, and the most common are molecules related to angiogenesis. Higher levels of soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG), as well as lower levels of placental growth factor (PIGF) were demonstrated before and after preeclampsia onset6,7, making of these molecules good candidates for the early diagnosis of this syndrome. However, despite the several promising candidates, their clinical validity is still to be established. Although urine samples are advantageous due to its easy, fast and non-invasive collection, and larger volume, research of biomarkers has still been largely focused in plasma/serum samples, thus, the amount of studies related to predictive markers in urine are still scarce.

Maternal systemic inflammation and endothelial dysfunction are consider hallmarks of preeclampsia8,9 and increased adhesion molecules10 as well as proinflammatory cytokines11 were reported in these patients, what may contribute to leukocyte activation and affect endothelial function. A pro-inflammatory molecule able to trigger endothelial dysfunction is the enzyme myeloperoxidase (MPO)12, which can impair the vasodilator nitric oxide13, reduced in preeclampsia11, and generate reactive species contributing for unleashing and perpetuation of the endothelial dysfunction and hypertensive state13. Moreover, studies pointed MPO as a possible biomarker for some cardiovascular conditions such as coronary artery disease15 and atherosclerosis16, but although higher levels of MPO has been demonstrated during preeclampsia15–18, there is still no investigation of this enzyme before the disease onset and its predictive potential for this disorder.

1Department of Pharmacology, Institute of Biosciences of Botucatu, Universidade Estadual Paulista (UNESP), Distrito Rubião Junior, Botucatu, São Paulo, 18680-000, Brazil. 2Department of Pediatrics, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, 14049-900, Brazil. 3Department of Gynecology and Obstetrics, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, 14049-900, Brazil. Correspondence and requests for materials should be addressed to V.C.S. (email: valeria.sandrim@ibb.unesp.br)
Therefore, this study aimed to explore MPO concentration and activity in both plasma and urine samples from pregnant women before preeclampsia onset, in order to verify if this enzyme is a potential biomarker for preeclampsia diagnosis.

Results
General characteristics for controls who remained healthy throughout pregnancy and for cases who later developed mild or severe preeclampsia are summarized in Table 1. No differences in maternal age, smoke, body mass index and gestational age at sampling were observed. Systolic blood pressure was increased in the severe case group and diastolic blood pressure were also increased in both severe and mild case groups when compared with control group. Besides, severe cases presented lower newborn weight and a higher percentage of small for gestational age infants compared to controls, this group also had lower gestational age at delivery when compared to both controls and mild cases.

While investigating plasma MPO concentration (Fig. 1A) and activity (Fig. 1B) no statistical differences were observed among subjects who remained normotensive throughout pregnancy (controls) and those who developed any of the two forms of preeclampsia (mild and severe cases) ($P = 0.6$ and $P = 0.2$, respectively). However, despite no statistical significance, it is possible to observe a slight decrease in enzymatic activity in the group of severe cases when compared to controls ($P = 0.2$; $76.7 \pm 35.6 \text{ U/L}$ vs $57.0 \pm 23.6 \text{ U/L}$, respectively).

Regarding MPO measurements in urine samples, similarly to plasma, we did not found significant differences in enzyme concentration (Fig. 2A) nor activity (Fig. 2B) between controls and mild/severe cases ($P = 0.2$ and $P = 0.2$, respectively).

Table 1. General characteristics of patients enrolled in the study. Information of this table is referent to the moment of blood and urine collection before preeclampsia diagnosis, except for GA at delivery, NBW and SGA. Data as mean ± SD or n (percentage of total). BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; PE, preeclampsia; NA, non-applicable; GA, gestational age; NBW, newborn weight; SGA, small for gestational weight. *vs healthy pregnant; †vs mild preeclampsia.

| Parameters                  | Healthy pregnant (control) | Preeclampsia (case) | $P$  |
|-----------------------------|----------------------------|---------------------|------|
|                             | n 57                       | Mild 16             | 14   |
| Age (years)                 | 25.6 ± 6.2                 | 27.1 ± 5.6          | 29.0 ± 5.8     | 0.16 |
| Current smoker              | 5 (8.8)                    | 3 (18.7)            | 2 (14.3)      | 0.51 |
| BMI (Kg/m²)                 | 29.4 ± 5.8                 | 29.4 ± 5.0          | 28.3 ± 5.3    | 0.80 |
| SBP (mmHg)                  | 109.1 ± 10.5               | 114.8 ± 9.8         | 119.3 ± 13.4* | 0.005 |
| DBP (mmHg)                  | 66.0 ± 6.6                 | 71.9 ± 6.5*         | 75.9 ± 10.8*  | <0.000 |
| GA at sampling (weeks)      | 23.1 ± 2.2                 | 23.6 ± 1.4          | 23.1 ± 1.1    | 0.43 |
| GA at delivery (weeks)      | 39.7 ± 1.7                 | 38.8 ± 1.1          | 35.1 ± 4.3**  | <0.000 |
| Nulliparous                 | 22 (38.6)                  | 7 (43.7)            | 4 (28.6)      | 0.68 |
| NBW (g)                     | 3343.0 ± 495.1             | 3370.0 ± 520.9      | 2364.0 ± 1011.0** | <0.000 |
| SGA (%)                     | 2 (3.6)                    | 2 (12.5)            | 6 (42.9)*     | <0.000 |

Figure 1. Plasma MPO concentration (A) and activity (B) from pregnant women who subsequently developed mild ($n = 14$) and severe ($n = 14$) preeclampsia (PE), and those that remained normotensive throughout pregnancy (HP; $n = 56$). No significant difference on MPO levels ($P = 0.6$) nor activity ($P = 0.2$) between HP (12.5 ± 4.7 ng/mL and 76.7 ± 35.6 U/L), mild PE (11.7 ± 4.3 ng/mL and 72.3 ± 29.3 U/L) and severe PE (11.4 ± 5.0 ng/mL and 57.0 ± 23.6 U/L) respectively. Data as mean ± SD. Comparison between groups were by ANOVA 1-way followed by Tukey’s multiple comparisons test.
not shown). Others pointing no differences19–21. Although urine samples are able to provide important information about severe conditions of the organism with a fast, simple and non-invasive collection, no previous study has investigated MPO parameters in this matrix from preeclamptic patients. Besides, none has explored a possible contribution of this enzyme for early diagnosis of this disorder.

In this study, we aimed to explore MPO concentration and activity in both plasma and urine samples from pregnant women who subsequently developed preeclampsia in order to verify if this molecule could be useful for early diagnosis of this disease. To our knowledge, we are the first to investigate the potential of MPO for preeclampsia prediction. However, plasmatic as well as urinary MPO concentration and activity showed no significant difference between healthy controls and pregnant women who later developed mild or severe preeclampsia.

Previous studies have investigated MPO in established preeclampsia, some reporting higher concentration15,16 and activity17,18 in plasma/serum samples from preeclamptic patients compared to healthy pregnant women, and others pointing no differences19–21. Although urine samples are able to provide important information about several conditions of the organism with a fast, simple and non-invasive collection, no previous study has investigated MPO parameters in this matrix from preeclamptic patients. Besides, none has explored a possible contribution of this enzyme for early diagnosis of this disorder.

In both sample matrix, we did not found any difference in enzyme levels or activity when comparing controls, mild and severe cases, similarly to Hung et al.19, who also observed no differences in plasma MPO levels at 15–20 weeks gestation between healthy pregnant women and women who developed preeclampsia, thus suggesting that the increase in MPO observed by others15,16 after preeclampsia diagnosis may be a consequence instead of a trigger for the disorder. Although no statistical differences has been found in MPO parameters between control and cases, a decreasing trend can be observed in urine MPO concentration and in plasma MPO activity on patients with severe preeclampsia. This decreasing trend might be related to the severity of the disease itself; higher blood pressure as well as other complications of the severe form of the disease may contribute to the oxidative state, resulting in increased levels of reactive oxygen species as superoxide and hydrogen peroxide. These reactive species when in high levels are able to inactivate MPO by converting the molecule to an inactive form, and to change the enzyme structure by destructing the heme-groups and iron release13,22. Moreover, ceruloplasmin levels, increased in preeclampsia23, as well as some polyphenols derived from diet can affect MPO by reacting directly with the enzyme, thus decreasing its activity, or by reacting with its end products24,25.

A possible explanation for the lack of difference in MPO parameters between the groups when comparing to other studies is the gestational age at sampling. Previous studies15–18 that reported some differences in MPO

![Figure 2.](image)

Discussion

In order to investigate some possible association, we correlated MPO concentration and activity in both plasma and urine samples between itself, with maternal age, body mass index, systolic and diastolic blood pressure, gestational age at sampling, newborn weight (Table 2) and smoking status. Despite no statistical difference in body mass index among the three groups, a positive correlation (P = 0.02; r = 0.6) between body mass index and plasma MPO concentration in severe case group was found (Supplementary Figure S1A). Also among severe cases, a negative correlation (P = 0.01; r = −0.7) was observed between plasma MPO activity and systolic blood pressure (Supplementary Figure S1B). In control group, it was found a significant positive correlation (P = 0.01; r = 0.4) between MPO concentration and activity in urine samples (Supplementary Figure S1C). No other statistically significant correlations were found. Concerning to the differences in MPO related to smoking status, this characteristic do not seems to influence in MPO concentration nor activity (P ≥ 0.2 and P ≥ 0.1, respectively; data not shown).

In this study, we aimed to explore MPO concentration and activity in both plasma and urine samples from pregnant women who remained normotensive throughout pregnancy and those who subsequently developed preeclampsia in order to verify if this molecule could be useful for early diagnosis of this disease. To our knowledge, we are the first to investigate the potential of MPO for preeclampsia prediction. However, plasmatic as well as urinary MPO concentration and activity showed no significant difference between healthy controls and pregnant women who later developed mild or severe preeclampsia.

Previous studies have investigated MPO in established preeclampsia, some reporting higher concentration15,16 and activity17,18 in plasma/serum samples from preeclamptic patients compared to healthy pregnant women, and others pointing no differences19–21. Although urine samples are able to provide important information about several conditions of the organism with a fast, simple and non-invasive collection, no previous study has investigated MPO parameters in this matrix from preeclamptic patients. Besides, none has explored a possible contribution of this enzyme for early diagnosis of this disorder.

In both sample matrix, we did not found any difference in enzyme levels or activity when comparing controls, mild and severe cases, similarly to Hung et al.19, who also observed no differences in plasma MPO levels at 15–20 weeks gestation between healthy pregnant women and women who developed preeclampsia, thus suggesting that the increase in MPO observed by others15,16 after preeclampsia diagnosis may be a consequence instead of a trigger for the disorder. Although no statistical differences has been found in MPO parameters between control and cases, a decreasing trend can be observed in urine MPO concentration and in plasma MPO activity on patients with severe preeclampsia. This decreasing trend might be related to the severity of the disease itself; higher blood pressure as well as other complications of the severe form of the disease may contribute to the oxidative state, resulting in increased levels of reactive oxygen species as superoxide and hydrogen peroxide. These reactive species when in high levels are able to inactivate MPO by converting the molecule to an inactive form, and to change the enzyme structure by destructing the heme-groups and iron release13,22. Moreover, ceruloplasmin levels, increased in preeclampsia23, as well as some polyphenols derived from diet can affect MPO by reacting directly with the enzyme, thus decreasing its activity, or by reacting with its end products24,25.

A possible explanation for the lack of difference in MPO parameters between the groups when comparing to other studies is the gestational age at sampling. Previous studies15–18 that reported some differences in MPO

In this study, we aimed to explore MPO concentration and activity in both plasma and urine samples from pregnant women who subsequently developed preeclampsia in order to verify if this molecule could be useful for early diagnosis of this disease. To our knowledge, we are the first to investigate the potential of MPO for preeclampsia prediction. However, plasmatic as well as urinary MPO concentration and activity showed no significant difference between healthy controls and pregnant women who later developed mild or severe preeclampsia.

Previous studies have investigated MPO in established preeclampsia, some reporting higher concentration15,16 and activity17,18 in plasma/serum samples from preeclamptic patients compared to healthy pregnant women, and others pointing no differences19–21. Although urine samples are able to provide important information about several conditions of the organism with a fast, simple and non-invasive collection, no previous study has investigated MPO parameters in this matrix from preeclamptic patients. Besides, none has explored a possible contribution of this enzyme for early diagnosis of this disorder.

In both sample matrix, we did not found any difference in enzyme levels or activity when comparing controls, mild and severe cases, similarly to Hung et al.19, who also observed no differences in plasma MPO levels at 15–20 weeks gestation between healthy pregnant women and women who developed preeclampsia, thus suggesting that the increase in MPO observed by others15,16 after preeclampsia diagnosis may be a consequence instead of a trigger for the disorder. Although no statistical differences has been found in MPO parameters between control and cases, a decreasing trend can be observed in urine MPO concentration and in plasma MPO activity on patients with severe preeclampsia. This decreasing trend might be related to the severity of the disease itself; higher blood pressure as well as other complications of the severe form of the disease may contribute to the oxidative state, resulting in increased levels of reactive oxygen species as superoxide and hydrogen peroxide. These reactive species when in high levels are able to inactivate MPO by converting the molecule to an inactive form, and to change the enzyme structure by destructing the heme-groups and iron release13,22. Moreover, ceruloplasmin levels, increased in preeclampsia23, as well as some polyphenols derived from diet can affect MPO by reacting directly with the enzyme, thus decreasing its activity, or by reacting with its end products24,25.

A possible explanation for the lack of difference in MPO parameters between the groups when comparing to other studies is the gestational age at sampling. Previous studies15–18 that reported some differences in MPO
between preeclampsia and healthy pregnant women evaluated samples collected with a gestational age above 30 weeks, while our samples were collected about 23 weeks of gestation, what might indicate that the increased MPO in preeclampsia pointed by others may not be a causative factor but a result of the established disease. It is known that, by the end of second trimester, poor trophoblast invasion and consequently impaired remodeling of the uterine spiral arteries result in a placental ischemia with a subsequent release of bioactive factors in maternal circulation of preeclampsia patients. Some of these factors, mostly proinflammatory cytokines as TNFα, as well as the hypoxic condition itself, could stimulate activation of neutrophils and release of MPO from those cells. Moreover, Hung et al. demonstrated an increase in oxidative stress on healthy pregnant women on the third trimester (above 26 weeks of gestation) which could also improve MPO activity due to the higher availability of co-factors as superoxide and hydrogen peroxide.

Analyzing correlations of MPO with other parameters, we observed a positive correlation in severe case group between plasma MPO concentration and body mass index. Among other maternal characteristics, obesity is considered a risk factor for the development of preeclampsia as demonstrated by Bodnar and cols\(^29,30\), which observed that elevated body mass index increased the incidence of both mild and severe forms of this disorder. In the past years, obesity cases have been increasing considerably, and one of its results is the chronic inflammatory status triggered by the metabolic excess and adipose tissue activation, which leads to production and release of substances able to modulate the inflammatory and immune response\(^31\). This condition contribute to macrophage and neutrophil activation and consequent release of MPO, which was demonstrated to be increased in obese subjects in the study of Borato et al.\(^32\). Moreover, Shukla et al.\(^33\) demonstrated greater MPO staining in systemic vasculature from both obese and preeclamptic women, suggesting that overweight women could display higher risk for developing this disorder. There was also a negative correlation in severe case group between plasma MPO concentration and systolic blood pressure that, although unexpected, might suggest an attempt by the organism to normalize the blood pressure, already increased, in the presence of a molecule which contribute to vasoconstriction (mostly through nitric oxide consumption).

Some authors also investigated MPO levels in placental samples, but the results obtained were contradictory. Gandley et al.\(^16\) observed higher levels of the enzyme in placent al extracts from patients with preeclampsia compared with normal pregnant women, while Hung et al.\(^17\) reported no differences between the groups. One of the reasons for this difference between authors might be the placental sampling site; in the work of Gandley et al.\(^16\) MPO was quantified in a single site of placenta, while Hung et al.\(^17\) measured the enzyme in a pool of different sites of the organ, what might influence the final levels of MPO.

Although we were the first to investigate MPO predictive potential in preeclampsia by measuring both concentration and activity in two different matrices (plasma and urine), this study present some limitations. As a convenience cohort, the BRISA cohort was finished once sample number was reached, and this cohort does not restrict patients with previous diseases. Moreover, we did not evaluated MPO parameters in placental samples, so we do not know the enzyme levels nor activity in this organ among our subjects. Another limitation might be related to the method applied for MPO activity that, although still one of the most common applied so far\(^34\), due to the lack of a standard method for plasma/urine samples might present some interferences generally in the presence of other peroxidases. However, we have demonstrated\(^35\) that most of the enzymatic activity assessed in plasma samples using the colorimetric method with TMB (tetramethylbenzidine) as substrate is mainly referent to MPO activity, once we observed that enzymatic activity detection decreased in more than 90% after addition of 4-aminobenzoic acid hydrazide, a MPO specific and irreversible inhibitor. Therefore, although susceptible to some interferences, it seems to be a reasonable method for assessment of MPO activity.

In conclusion, this study did not find any evidence that MPO, concentration or activity, was elevated before the diagnosis of preeclampsia, probably because the MPO increase might happen as a result from proinflammatory stimulus after the establishment of the disease. However, the correlation between body mass index and MPO levels suggest an increased risk for the development of this disorder. Therefore, in view of the results, MPO does not seem to display a potential use as a marker for preeclampsia prediction.

### Table 2. Correlations between general characteristics and MPO concentration and activity in plasma and urine samples from controls, mild and severe cases Data as P value (correlation coefficient).; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; GA, gestational age; NBW, newborn weight. Statistically significant (P ≤ 0.05).

| Parameters          | Healthy pregnant (controls) | Mild preeclampsia (case) | Severe preeclampsia (case) |
|---------------------|----------------------------|-------------------------|----------------------------|
|                     | Plasma                     | Urine                   | Plasma                     | Urine                   | Plasma                     | Urine                   |
|                     | Conc. | Activity | Conc. | Activity | Conc. | Activity | Conc. | Activity | Conc. | Activity | Conc. | Activity |
| SBP (mmHg)          | 0.41(−0.1) | 0.5(−0.1) | 0.4(−0.1) | 0.6(−0.1) | 0.3(−0.3) | 0.6(−0.1) | 1.0(−0.0) | 0.6(0.1) | 0.5(0.2) | 0.01(0.7) | 0.3(−0.3) | 0.9(0.0) |
| DBP (mmHg)          | 0.7(−0.0) | 0.5(0.1) | 0.7(−0.0) | 1.0(−0.0) | 0.1(−0.4) | 0.1(−0.4) | 0.7(−0.1) | 0.5(−0.2) | 0.6(0.1) | 0.1(−0.6) | 0.1(−0.5) | 0.3(0.3) |
| BMI (Kg/m\(^2\))    | 0.40(0.1) | 0.5(0.1) | 0.7(−0.1) | 0.2(−0.4) | 0.2(−0.3) | 0.2(−0.3) | 0.5(−0.2) | 0.02(0.6) | 0.6(0.2) | 0.4(−0.2) | 0.3(0.3) |
| Maternal age (years)| 0.5(−0.1) | 0.7(0.1) | 0.7(0.0) | 1.0(−0.0) | 0.8(−0.1) | 0.1(−0.5) | 0.8(−0.1) | 0.7(0.1) | 0.4(−0.3) | 0.6(0.2) | 0.7(−0.1) | 0.8(−0.1) |
| GA at sampling (weeks)| 0.6(−0.1) | 0.7(0.1) | 0.7(−0.0) | 0.7(−0.0) | 0.5(−0.2) | 0.7(0.1) | 0.6(−0.1) | 0.4(−0.2) | 0.6(0.2) | 0.7(0.1) | 1.0(−0.0) | 0.9(0.0) |
| NBW (g)             | 0.5(−0.1) | 0.8(−0.0) | 0.5(−0.1) | 0.5(0.1) | 0.1(−0.5) | 0.9(0.0) | 0.8(0.1) | 0.8(0.1) | 0.7(−0.1) | 0.4(0.3) | 0.4(0.3) | 0.3(0.3) |
| MPO levels × activity| 0.3(0.1) | 0.01(0.4) | 0.5(−0.2) | 0.6(0.1) | 0.5(0.2) | 0.5(−0.2) |
Material and Methods

Subjects. This predictive study is part of a more broad observational study accomplished in two Brazilian cities (BRISA)\(^3\). A total of 1,417 pregnant women were evaluated at Hospital das Clínicas of Ribeirão Preto—University of São Paulo at 20-25 weeks of gestation (Prenatal cohort), from these 17 did not return and 460 gave birth in other units outside the institution. From the 940 pregnant remaining, 30 developed preeclampsia (cases) and 58 healthy pregnant women were drawn from the remaining healthy pregnant group; subjects’ selection is outlined in Supplementary Figure S2. Preeclampsia was defined following guidelines of NHBPEP\(^37\) (National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy). Severity of the disorder was defined according to the American College of Obstetricians and Gynecologists\(^1\), and preeclampsia was classified as severe when systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥110 mmHg or in the presence of manifestations as thrombocytopenia, impaired liver function, progressive renal insufficiency, pulmonary edema and cerebral or visual disturbances. All participants provided written informed consent, and the study was approved by Institutional Review Board of the University of Sao Paulo, Ribeirão Preto (reference 4116/2008), according to the declaration of Helsinki. Maternal venous blood samples were collected in Vacutainer tubes (Becton-Dickinson, São Paulo, Brazil) with EDTA as anticoagulant. Samples were centrifuged at room temperature and plasma were stored at −80°C until analysis.

Myeloperoxidase concentration and activity. MPO concentration was evaluated in plasma/urine samples using a commercial ELISA kit (Human Myeloperoxidase DuoSet ELISA - R&D Systems, Minneapolis, MN, USA) with standard range between 62.5–4,000.0 pg/mL. Plasma, but not urine, samples were diluted 1:100 in reagent buffer, blocked with 1% BSA in PBS and optical density was determined at 450 nm using in a microplate reader (Synergy 4–BioTek, Winooski, VT, USA). Intra-assay of 1.25% and 1.98% for urine and plasma analysis, respectively. MPO activity was determined based in the method of Bradley et al.\(^38\) by measuring tetramethylbenzidine (TMB) oxidation in the presence of hydrogen peroxide. Briefly, 30 mL of urine/plasma (plasma diluted 1:100 in PBS) were incubated with 20 mL of PBS and 100 mL of liquid substrate system (Sigma, St. Louis, MO, USA), composed by TMB and hydrogen peroxide, at 37°C for 10 minutes protected from light. After incubation, the reaction was blocked with 100 µl sulfuric acid 2 N and optical density were determined at 450 nm. A standard curve (range 0.153–2500 mU/50 µL) was generated by incubation of horseradish peroxidase with the previous reagents. Intra-assay of 5.45% and 2.51% for urine and plasma analysis, respectively.

Statistical analysis. Statistical analysis was performed with GraphPad Prism for Windows, version 6.01 (GraphPad Software, San Diego, CA, USA). Categorical variables were compared by χ2 tests and continuous variables were compared by Student t test, ANOVA followed by Tukey test (for normally distributed variables) or Mann-Whitney’s test, Kruskal-Wallis followed by Dunn’s multiple comparison test (for not normally distributed variables). Correlations were analyzed using Pearson’s test, except for MPO levels x activity that were analyzed by Spearman test. For all tests a probability value of P < 0.05 was considered significant.

References
1. ACOG. Hypertension in Pregnancy. Obst. Gynecol. 122, 1122–1131 (2013).
2. English, F. A., Kenny, L. C. & McCarthy, F. P. Risk factors and effective management of preeclampsia. Integrated Blood Pressure Control 8, 7–12 (2015).
3. Cuffe, J. S. M., Holland, O., Salomon, C., Rice, G. E. & Perkins, A. V. Review: Placental derived biomarkers of pregnancy disorders. Placenta 17, 1–7 (2017).
4. Powe, C. E., Levine, R. J. & Karumanchi, S. A. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 123, 2856–2869 (2011).
5. Roberts, J. M., Taylor, R. N. & Goldfinen, A. Clinical and Biochemical-Evidence of Endothelial-Cell Dysfunction in the Pregnancy Syndrome Preeclampsia. Am. J. Hypertens. 4, 700–708 (1991).
6. Shah, D. A. & Khalil, R. A. Bioactive factors in uteroplacental and systemic circulation link placental ischemia to generalized vascular dysfunction in hypertensive pregnancy and preeclampsia. Biochem. Pharmacol. 95, 211–226 (2015).
7. Levine, R. J. et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350, 672–83 (2004).
8. Oliveira, L. G. D., Karumanchi, A. & Sais, N. Pre-eclampsia: estresse oxidativo, inflamação e disfunção endotelial. Rev. Bras. Ginecol. e Obst. 32, 609–616 (2010).
9. Possomato-Vieira, J. S. & Khalil, R. A. Mechanisms of Endothelial Dysfunction in Hypertensive Pregnancy and Preeclampsia. Advances in Pharmacology 77, 361–431 (2016).
10. Chaiworapongsa, T. et al. Soluble adhesion molecule profile in normal pregnancy and pre-eclampsia. J. Matern. Fetal Neonatal Med. 12, 19–27 (2002).
11. Sandrin, V. C. et al. Nitric oxide formation is inversely related to serum levels of antiangiogenic factors soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia. Hypertension 52, 402–407 (2008).
12. Meuwese, M. C. et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J. Am. Coll. Cardiol. 50, 159–165 (2007).
13. Nussbaum, C., Klinke, A., Adam, M., Baldus, S. & Sperandio, M. Myeloperoxidase: a leukocyte-derived protagonist of inflammation and cardiovascular disease. Antioxid. Redox Signal. 18, 692–713 (2013).
14. Karakas, M. & Koenig, W. Myeloperoxidase Production by Macrophage and Risk of Atherosclerosis. Curr. Atheroscler. Rep. 14, 277–283 (2012).
15. Mellembakken, J. R. et al. Increased systemic activation of neutrophils but not complement in preeclampsia. Obstet. Gynecol. 97, 371–374 (2001).
16. Gandy, R. E. et al. Increased Myeloperoxidase in the Placenta and Circulation of Women With Preeclampsia. Hypertension 52, 387–393 (2008).
17. Kurodugu, Z., Ottol, H., Kurdoglu, M. & Kamaci, M. Evaluation of the relationship between adenosine evaluation of the relationship between adenosine deaminase, myeloperoxidase, cholinesterase, preeclampsia severity, and neonatal outcomes. Clin. Exp. Hypertens. 34, 493–497 (2012).
18. Noyan, T., Ramazan, M., Lu, E. & Kamaci, M. Serum advanced oxidation protein products, myeloperoxidase and ascorbic acid in pre-eclampsia and eclampsia. Aust. N. Z. J. Obstet. Gynecol. 46, 486–491 (2006).
19. Hung, T. et al. Myeloperoxidase in the plasma and placenta of normal pregnant women and women with pregnancies complicated by preeclampsia and intrauterine growth restriction. Placenta 33, 294–303 (2012).
31. Gregor, M. F. & Hotamisligil, G. S. Inflammatory mechanisms in obesity. 
32. Borato, D. C. K. 
33. Shukla, J. & Walsh, S. W. Neutrophil release of myeloperoxidase in systemic vasculature of obese women may put them at risk for 
34. Pulli, B. 
35. Rocha-Penha, L., Caldeira-Dias, M., Tanus-Santos, J. E., de Carvalho Cavalli, R. & Sandrim, V. C. Myeloperoxidase in hypertensive 
36. da Silva, A. A. 
37. Magee, L. A., Pels, A., Helewa, M., Rey, E. & von Dadelszen, P. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. 
38. Bradley, P. E., Priebat, D. A., Christensen, R. D. & Rothstein, G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. 

Acknowledgements
The authors acknowledge the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq-Brazil), the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES-Brazil), and the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP-Brazil) for financial help, as well as the team involved in BRISA study.

Author Contributions
L.R.P. performed all experiments, statistical analysis and drafted the manuscript. V.C.S. designed the study and revised the final manuscript. H.B., M.A.B., V.C.C. and R.C.C. designed and performed the BRISA study and review the manuscript.

Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-09272-4

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017